New DH calendar
Article updated: 12/7/2012 4:11 PM

Drug makers’ interference with generics gets high court review

Buy this photo Buy this photo
Gallery Image

Associated Press/Oct. 9, 2012 Federal Trade Commission (FTC) Chairman Jon Leibowitz speaking at the Justice Department in Washington.

About this Article

The Supreme Court will take a close look at payments from brand-name drug makers to manufacturers of generic equivalents to keep the no-name products off the market at an estimated cost of $3.5 billion a year to consumers.